Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration

Manufacturing, Gene Therapies

Latest News


Latest Videos


Shorts

FDA Investigates Cancer Risk in Novartis' Gene Therapy
1:07
FDA Investigates Cancer Risk in Novartis' Gene Therapy
8 days ago
by
Emily Schoenthaler

More News

Multiple green adeno-associated virus capsid particles on a white background. | Image Credit: © Mr_Microbe - stock.adobe.com

uniQure submitted a Biologics License Application to the FDA and a Marketing Authorisation Application to the UK's MHRA for ifezuntirgene inilparvovec (AMT-130), an AAV5 gene therapy for Huntington's disease, based on three-year Phase I/II data — a potential first disease-modifying treatment for a condition with no approved therapies that slow progression.